{"url_path":"/sec/sln/8-k/2026-06-11/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-266705-index.html","accession_number":"0001193125-26-266705","cik":"0001479615","ticker":"SLN","issuer_name":"Silence Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-266705-index.html","primary_entity_key":"0001479615","primary_entity_name":"Silence Therapeutics plc"},"word_count":175,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 11, 2026, Silence Therapeutics plc issued a press release highlighting follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) presented at the European Hematology Association (EHA) 2026 Annual Congress. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.\n\nThe information in this Item 8.01 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing."}